Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.77% $0.935
America/New_York / 25 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3.02 mill |
EPS: | -35.10 |
P/E: | -0.0300 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 3.23 mill |
Avg Daily Volume: | 0.0295 mill |
RATING 2024-03-25 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.0300 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.343 (-136.67%) $-1.277 |
Date: 2024-03-31 |
Expected Trading Range (DAY) |
---|
$ 0.0807 - 1.789 ( +/- 91.37%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Alloway Paul | Buy | 23 530 | Common Stock |
2024-03-25 | Alloway Paul | Sell | 18 090 | Restricted Stock Units |
2024-03-25 | Michaud Charles Jr | Buy | 6 448 | Common Stock |
2024-03-25 | Michaud Charles Jr | Sell | 5 360 | Restricted Stock Units |
2024-01-01 | Tzianabos Arthur | Buy | 19 140 | Common Stock |
INSIDER POWER |
---|
36.03 |
Last 94 transactions |
Buy: 1 681 707 | Sell: 632 243 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.935 (0.77% ) |
Volume | 0.401 mill |
Avg. Vol. | 0.0295 mill |
% of Avg. Vol | 1 359.29 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.